Pharmacology of dexlansoprazole and its application in treating gastroesophageal reflux disease
Abstract
Although proton pump inhibitors(PPI) have achieved a remarkable success in the management of gastroesophageal reflux disease(GERD).However,the challenges such as insufficient action duration and poor compliance still exist as the reason for treatment failure.Recently,dexlansoprazole dual delayed release(DDR,Takeda Pharmaceuticals) under the trade name of DexilantTM got approved by FDA,which provides longer duration of action and more effective acid suppression.It is currently approved for the treatment of erosive esophagitis(acute,maintenance) and symptom release of NERD.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.